Wright, Sarah L;
Ananthavarathan, Piriyankan;
Satish, Madhumita R;
Malladi, Prasad;
Pakzad, Mahreen;
Simeoni, Sara;
Panicker, Jalesh N;
(2023)
Delivery of urethral sphincter botulinum toxin injections for treating urinary retention during the COVID19 pandemic.
Continence Reports
, 6
, Article 100031. 10.1016/j.contre.2023.100031.
Preview |
Text
Ananthavarathan_Delivery of urethral sphincter botulinum toxin injections for treating urinary retention during the COVID19 pandemic_VoR.pdf - Published Version Download (259kB) | Preview |
Abstract
Aims: Urethral sphincter botulinum toxin injections is an alternative treatment for urinary retention in women with Fowler’s syndrome and when access to health services were curtailed during the Covid19 pandemic, we continued to offer treatment to prevent increased demand on catheter services due to a recurrence of urinary retention. We describe our experience delivering safe and timely treatment during this period of lockdowns and restricted access to healthcare. // Methods: We retrospectively reviewed the records of all women with Fowler’s syndrome treated with transperineal urethral sphincter botulinum toxin injection between 23rd March 2020 and 31st December 2021 in a tertiary university hospital and clinical outcomes were recorded. // Results: 15 women (mean age 35.6 ± 10.1 years) received 100U OnabotulinumtoxinA injected into the external urethral sphincter as an out-patient procedure adopting hospital infection control guidelines. 41 injections were administered in total, and 8 (53%) patients received more than 1 injection (median 2 injections/patient, median inter-injection interval 108.5 days). 10 (66.7%) patients reported improvements in urinary symptoms across 31/41 (75.6%) of injections. Side effects were reported after 21.4% of injections which were mild and transient. No patients developed Covid19 within 4 weeks of the hospital visit. // Conclusion: Real-world data shows that transperineal urethral sphincter botulinum toxin injections could be continued safely and effectively during the Covid19 pandemic. This essential outpatient service played an important role in treatment and quality of life for women with Fowler’s syndrome, and avoided an additional burden on the NHS at the time of a health crisis.
| Type: | Article |
|---|---|
| Title: | Delivery of urethral sphincter botulinum toxin injections for treating urinary retention during the COVID19 pandemic |
| Open access status: | An open access version is available from UCL Discovery |
| DOI: | 10.1016/j.contre.2023.100031 |
| Publisher version: | https://doi.org/10.1016/j.contre.2023.100031 |
| Language: | English |
| Additional information: | Copyright © 2023 The Authors. Published by Elsevier B.V. on behalf of International Continence Society. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/). |
| Keywords: | Neuro-urology; Botulinum toxin; Transperineal; Health delivery; Urethral sphincter; Urinary retention |
| UCL classification: | UCL UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Brain Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Brain Sciences > UCL Queen Square Institute of Neurology UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Brain Sciences > UCL Queen Square Institute of Neurology > Neuroinflammation |
| URI: | https://discovery.ucl.ac.uk/id/eprint/10174490 |
Archive Staff Only
 |
View Item |
